India's Sun Pharma aims to launch its obesity drug in five years, managing director says
India's largest drugmaker by revenue Sun Pharmaceutical is aiming to launch its experimental anti-obesity and type 2 diabetes ...
Investor's Business Daily on MSN2h
Behind Hims Stock's Roller-Coaster Ride As Weight-Loss Drugs Battle Heats Up
Hims & Hers Health has blazed a red-hot streak, helped by the growing popularity of weight-loss drugs. But after a massive ...
Irish Examiner on MSN18h
On the rebound: What are the long-term risks of Ozempic?
Ahead of World Obesity Day, we examine the impact of the game-changing drugs that control appetite. Increasingly being taken ...
pharmaphorum19h
FDA rejects Novo Nordisk’s weekly basal insulin
Novo Nordisk’s bid to provide a once-weekly basal insulin product for people with diabetes, reducing the number of injections needed, has hit a major hurdle in the US. The FDA sent the Danish ...
Wall Street Journal18h
Novo Nordisk A/S ADR
$ 84.0918 0.0618 0.07% ...
Bloomberg L.P.18h
Novo Nordisk A/S
Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world ...